Folks I've just received a response to my email here it is --- not sure whether the Dutch/ZonMW data [will be comparable to/can be combined with] the UK (DecodeME) data so I'm posting it here i.e. to get your views!
@Andy
"
Dear Francis,
You had some questions regarding my project studying the genetic background of ME/CFS. see below for my reply
The project consists out of a world-wide GWAS meta-analysis, meaning every study participating (biobank, dataset, patient population etc) will perform the same GWAS and share the results with me, which will then be Meta-analysed. For this to be reliable and robust large sample sizes are needed (hence the world-wide collaboration) and from our power calculation, also part of our application, and genetic datasets available world-wide we calculated a sample size of 22.000- 42.000 cases.
- Total number of participants i.e GWAS?
As stated above, only results level data will be combined, this is the validated and standard practice in GWAS meta-analysis, there are set protocols for this that need to be followed. The benefit of this is that results form GWAS meta-analysis are very robust and reliable.
- Collaboration with DecodeME and data combination
From your message, however, I gather your questions relate not so much to sample size of specific GWAS methodology, but I suspect, your questions are more regarding the case definitions. I can assure you that my analysis plan has been examined and approved by multiple patients, ME/CFS experts, ME/CFS clinicians both national and international. I am a genetics and GWAS expert, I have worked in the GWAS field successfully for 10 years, I have studied multiple different subjects (predominantly osteoarthritis and (chronic) pain) which includes also complex phenotypes with multiple definitions/ways to measure. I am well aware of the problems regarding ME/CFS case criteria and all of the different criteria that exist. This is why my analysis plan contains state-of-the-art methods, multiple analysis and individual criteria specific sensitivity analysis in order to correctly analyse and define patients.
I hold my work to very high standards, and this project will be no different.
regards,
Dr. Cindy G. Boer
Postdoctoral researcher
Department of Internal Medicine
You could respond to her that her credentials weren't in question but that you'd like to know if the cohort she's going to be using is selected using the criteria set out by the research program. That is the CCC, ICC or IOM criteria for ME. And if people are clinically diagnosed. If they aren't, are they planning to diagnose them according to CCC, ICC or IOM criteria to find out if they are in fact ME-patients?